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Summary.-The in vitro chemosensitivity of primary monolayer cultures of human
ovarian tumours to a wide range of chemotherapeutic agents has been determined
using 3H-leucine incorporation as an index of cytotoxicity. Of 67 specimens received,
35 have been successfully cultured and tested for chemosensitivity. Drugs tested
included alkylating agents, antibiotics, antimitotics, antimetabolites and progesto-
gens. The overall incidence of efficacy of the drugs corresponded with the incidence
which might be expected from data on the clinical response rates produced by the
various drugs. Cultures from the tumour cells of treated patients generally showed
greater resistance than tumours of untreated patients. Correlation between in vitro
results and in vivo response was positive in all 8 patients receiving first-line chemo-
therapy and in 57oo (4/7) patients receiving second-line chemotherapy.
THE FIRST reported work on the use of
in vitro predictive tests for cancer chemo-
therapy in the individual was in 1957
(Wright et al., 1957) and subsequently
a number ofstudies have been undertaken
to evaluate the usefulness of such tests.
Several workers have used short-term
monolayer cultures for determination of
invitro chemosensitivityofhumantumours
(Berry et al., 1975; Dendy et al., 1970;
Holmes & Little, 1974; Limburg & Heck-
man, 1968) and good correlation between
in vitro chemosensitivity and clinical
response has been reported (Holmes &
Little, 1974; Limburg & Heckman, 1968;
Wheeler et al., 1974).
Recently, a microtest plate system for
cell-line growth and subsequent deter-
mination of chemosensitivity, using 3H-
leucine incorporation as an end-point for
cell death, has been described (Freshney
et al., 1975). The use of microtest plates
readily permits multiple drug testing, and
the present investigation was undertaken
with the aims of (i) using primary cultures
from human ovarian tumours to screen a
wide number of agents with potential
clinicalactivityagainstovarian carcinoma,
(ii) on that basis to use agents with marked
in vitro activity in the treatment of
ovarian cancer, and (iii) to correlate the
in vitro and in vivo data.
MATERIALS AND METHODS
Tumnouar material.-Material from patients
with histologically proven ovarian carcinoma
was used. This included 40 solid tumours, 23
ascitic fluids and 4 pleural fluids. The presence
of malignant cells in the samples received in
the laboratory was checked histologically.
Cultures were not used for sensitivity testing
if fibroblasts, recognized as areas of spindle-
shaped cells arrayed in parallel, were present
in large numbers, or ifthe growth pattern was
not characteristic of ovarian tumour cells as
described in the literature (Joachim et al.,
1974).
Cell preparation.-Sterile tumour biopsy
samples were transported to the laboratory in
Hanks' balanced salt solution with anti-
biotics. Necrotic and capsular material was
dissected away and the tissue minced finely.
After washing in phosphate-buffered saline
(PBS), the mince was transferred to a conical
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TABLE I. In vitro concentrations of drugs and peak plasma concentrations in humans
Drug
Actinomycin D
Adriamycin
Bleomycin
Chlorambucil
Cis-Platinum
Cyclophosphamide }
(Phosphoramide Mustard)
Cytosine arabinoside
5-Fluorouracil
Hexamethylmelamine
Methotrexate
6-Mercaptopurine
Medroxyprogesterone acetate
Methylprednisolone acetate
Mustine
Norethisterone acetate
Procarbazine
Thiotepa
Treosulfan
Vinblastine
Vincristine
Highest test
concentration*
(mg/ml)
5x 10-8
10-2
102
10-1
10-1
101-
10-1
10-2
10-1
10-2
10-1
10-1
10-1
10-2
10-1
101-
10-1
10-1
10-3
10-4
Dose
Peak plasma
concentration
(mg/ml)
15 ,ug/kg 7-5 x 10-5
30-60mg/mi2 5x 10-4
15mg/M2 2-4 x 10-3
0-6 mg/kg lilx 10-3
100mg/M2 2-49 x 10-3
720 mg 3-45 x 10-2
70mg/Mi2 5 5x 10-5
15 mg/kg 6 x 10-2
120-200 mg/m2 2 x 10-4-2 X10-
30mg/m2 2-75 x 10-3
500mg/Mi2 1-2 x 10-2
0-2 mg/kg 1.9x 10-4
0-025 mg/kg 6-4 x 10-5
References
Tattersall et at., 1975
Harris & Gross, 1975
Alberts et al., 1979a
Alberts et at., 1979b
Patton et al., 1978
Whiting et al., 1978
Dedrick et al., 1972
Finn & Sadee, 1975
2 D'Incalci et al., 1979
Bischoffet al., 1971
Coffey et al., 1972
Owellen et al., 1977a
Owellen et al., 1977b
* 2-3 concentrations were tested in logio increments.
flask containing 4-5 volumes of0 25% trypsin
and 50 ,tg/ml of DNA-ase (Sigma Chemical
Co.). The flask was shaken at 37°C for 20min
periods, and the supernatant decanted at the
end of each trypsinization period was imme-
diately centrifuged at 700 g for 5 min. The cell
pellet was resuspended in growth medium
(Eagle's Minimum Essential Medium, 20%
foetal bovine serum, 1mM glutamine, 2-2 g/l
sodium bicarbonate, 20 IU/ml penicillin,
20 ,ug/ml streptocmyin) and the process was
repeated either until tissue digestion was
complete or until enough viable cells had been
obtained. The final viable-cell concentration
was adjusted to 2 x 105/ml growth medium.
Ascitic and pleural fluids were collected in
sterile containers and were centrifuged at
700 g for 15 min. The cell pellet obtained was
often heavily contaminated with red blood
cells, which were eliminated by snap lysis.
Ten ml of sterile distilled water was added to
the cell pellet and the mixture agitated for
10-15 sec before the same volume of double-
strength bufferedmedium wasadded. Thiswas
repeated until all red blood cells had been
eliminated. The concentration of the final cell
pellet was adjusted to 2 x 105 viable cells/ml
of growth medium. Flat-bottomed microtest
plates (Linbro-Sterilin) were inoculated with
200[LIofcellsuspension per well andincubated
at 37°C in an atmosphere of 95% air/5% CO2.
Cultures were examined daily, and drugs were
added when the cultures were 40-50% con-
fluent.
Drugs-The following drugs have been
routinely tested: actinomycin D (Cosmagen:
Merk, Sharp and Dohme), adriamycin (Far-
mitalia Carlo Erba Ltd), bleomycin (Lund-
beck Ltd), chlorambucil (Burroughs Well-
come Ltd*),cis-platinum (II)-diammine di-
chloride (N.C.I.t), cyclophosphamide-phos-
phoramide mustard derivative (N.C.J.t
NSC-69945), cytosine arabinoside (Upjohn
Ltd*), 5-fluorouracil (Roche Products Ltd*),
hexamethylmelamine (N.C.I.t), 6-mercapto-
purine (Burroughs Wellcome Ltd*), metho-
trexate (Lederle Ltd*), mustine (Boots
Chemical Co.), norethisterone acetate (Scher-
ing Chemicals Ltd*), procarbazine (Roche
Products Ltd*), thiotepa (Lederle Ltd*),
treosulfan (Leo Labs Ltd*), vinblastine
(Velbe, Eli Lilly), vincristine (Oncovin, Eli
Lilly), warfarin (Duncan, Flockhartand Co.*),
medroxyprogesterone acetate (UpJohn Ltd*),
methylprednisolone acetate (UpJohn Ltd*).
Phosphoramide mustard is one ofthe active
metabolites of cyclophosphamide (Connors
et al., 1974), and was tested to avoid the neces-
* We are indebted to the above companies for their supply ofdrugs.
t These compounds were kindly supplied by the Drug Synthesis and Chemistry Branch, Division of
Cancer Treatment, National Cancer Institute, Bet,hesda, Maryland, U.S.A.
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sity for in vitro activation of the parent com-
pound.
All drug solutions were prepared imme-
diately before use, except actinomycin D,
vinblastine and vincristine, which were stored
up to 10 days at 4°C. Chlorambucil, hexa-
methylmelamine, 6-mercaptopurine, nore-
thisterone acetate, medroxyprogesterone ace-
tate and methyl prednisolone acetate were
suspended in 0-5% methyl cellulose to give a
stock drug concentration of 1 mg/ml. This
concentration of methyl cellulose was found
to be non-toxic to cells. All other drugs were
dissolved in growth medium to give a stock
concentration of 1 mg/ml. Drugs were tested
at 2-3 concentrations in loglo increments;
triplicate wells were used for each concentra-
tion and triplicate controls ofgrowth medium
only were included for each drug.
Drugs were tested over a concentration
range which included levels achievable in the
patient; in the absence of pharmacokinetic
data, drugs were tested at a maximum con-
centration of 10-1 mg/ml. Concentrations
tested, together with plasma levels, are shown
in Table I for all drugs used. Cultures were
exposed to the drugs for 48 h and then
allowed to recover for 24 h in medium only
before determination of the inhibitory effects
ofthe drugs.
Cytotoxicity determination. In earlier cul-
tures, inhibition ofgrowth was determined by
morphological assessment of the degree of
drug damage on haematoxylin- and eosin-
stained monolayers. Inhibition of 3H-leucine
incorporation was used on later cultures as an
index of drug effect. At the end of the 24 h
recovery, 100 ,ul of 20puCi/ml 3H-leucine
(L-4-5-3H-Leucine, Radiochemical Centre)
was added to each well and the plates were
incubated for 3 h at 37°C. The amount incor-
porated was assayed by previously described
methods (Freshney et al., 1975). The percent-
age inhibition produced by each drug and
drug concentration was calculated, and drug-
sensitivity histograms were plotted for indi-
vidual patients. Standard errors ofthe means
ranged from 1% to 100% routinely, with occa-
sional values of + 15%. Reproducibility be-
tween duplicate plates was in the same range.
It was not possible to test the day-to-day
reproducibility for surgical specimens, but
results obtained with cell lines using the same
assay system indicated that inter-experiment
variation was usually in the same range
(Wilson, unpublished data).
Clinical data
Thiotepa was routinely used as a single
agent, 30 mg being administered i.m. at 3-
weekly intervals when the platelet count was
> 105/mm3. When the platelet count was less
than this, thiotepa was withheld and 50 mg
Decadurabolin was administered. The two
combination regimes were also given once
every 3 weeks, the two regimes being 5-fluoro-
uracil (750 mg), actinomycin D (0 5 mg) and
thiotepa (30 mg), or vinblastine (2 mg),
actinomycin D (0 5 mg) and thiotepa (30 mg),
known as FATand VATrespectively. Patients
receiving combination therapy also received
radiotherapy.
Responses were considered complete when
there was alleviation ofsymptoms, disappear-
ance ofpalpable masses and absence ofascitic
fluid accumulation for more than 3 months.
Responses were considered partial when there
was alleviation of symptoms, either sub-
jectively or objectively for more than 3
months with first-line chemotherapy (first
choice of chemotherapy) or more than 1
monthwithsecond-linechemotherapy (chemo-
therapy given after relapse on first-line
chemotherapy).
RESULTS
Of 67 specimens received, 35 have been
successfully cultured and used for chemo-
sensitivity tests. These included 20/40
solid tumours and 15/23 ascitic fluids. No
successful cultures were obtained from 4
pleural fluids. Failure to establish cultures
was not always due to inadequategrowth
in vitro; other reasons included the absence
of malignant cells in fluid samples (based
on cytological evidence), heavy RBC
contamination, overgrowth of cultures by
fibroblasts and necrotic or contaminated
tumour specimens.
In vitro sensitivity to individual drug8
The tumour specimens exhibited con-
siderable variation in their degree of
sensitivity to the drugs in vitro. Experi-
mental variation was usually less than
± 15%, but considerably greater varia-
tions between specimens were found at
given drug concentrations. Variations in
sensitivity to the different drugs are shown
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FiG. 1. The range ofsensitivity to alkylating agents shown by cultures of tumouir cells from untreatedl
(A) and treated (B) patients. All concentrations are in mg/ml. CMB chlorambucil; PAM phosphora-
mide mustard; CIS cis-platinum; MUS mustine; TSPA thiotepa; TREO treosulfan.
in Figs 1-3; tumours from untreated and
treated patients are shown in (A) and (B)
respectively of each figure.
Alkylating agents
Results obtained with alkylating agents
are shown in Fig. 1. Cultures from treated
and untreated patients showed maximal
sensitivity to the highest concentration of
cis-platinum and phosphoramide mustard,
and most showed maximal sensitivity to
the highest concentration of chlorambucil,
mustine, thiotepa and treosulfan. Cultures
were also maximally sensitive to the
middle concentration of cis-platinum, but
showed considerable variations in their
sensitivity to the lowest concentration of
this drug, and to the two lower concentra-
tions of the other alkylating agents.
All treated patients had received thio-
tepa, either singly or in combination. At
10-2 mg/ml of thiotepa there was no
difference in the range of percentage
inhibition values between the treated and
untreated groups, but there was a differ-
ence at 10-3 mg/ml which had the effect
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TABLE II.-Percentage inhibitionproduced by a range ofalkylating agents against ovarian-
tumour culturesfrom individual patients
Patient* CMIBt- PLA
(10-2) (10-2)
1 164 741
2 10 92
3 8 87
4 19
0
6
24
24
32
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
49
47
35
E521
MIUS
(10-3)
29
z:1) .39}
38
:34
TSPA
(10- 2) ( I
74
32
39
11
16
91
:35
164 75 55 84
164 67 79 87
8
17
26
.34
16
39
0
16
28
31
29
24
17
32
28
20
38
55
49
29
24
F52]
48
25
43
27
8
E2
MI
577
36
58
37
TREO (IS
10-3) (10-2) (10-3)
46 187 69
62 13
23 13
10 7
19 0
26 48 56
0 29 22
36 28
20 42 M
54 63 791
66 79 97
20 60 28
0 38 93
9 33
15 34
17
37o (1
36 3 _
0 0
8 62 52
0 5 49
10 43 75
* 1-13 untreated; 14-22 previously treated patienits.
t Symbols as in Fig. 1; concentration shlown in mg/ml.
- indicates these drugs were not tested.
O boxed-in figures represent tumours classifie(d as sensitive to thtat
of steepening the dose-response curve in drug at v
the treated group. With phosphoramide curred al
mustard both treated and untreated point (seE
patients' tumours showed resistance at was seen
10-3 mg/ml when a 50% cut-off point was (10, 11).
used; untreated tumours still showed a in 2 unti
variation between 0 and 50% inhibition treated (]
at this concentration, whilst tumours from sensitivit
treatedpatientswere consistent inshowing showed c
<10% inhibition with this drug at this mustard
concentration, with a single exception. treosulfai
Similar differences between treated and parallel r
untreated groups were not apparent for phoramid
the other alkylating agents tested. lowered
Individual patients' tumours were thiotepa
looked at for their spectrum of sensitivity mustard,
to alkylating agents; these results are group sti
shown in Table II. Percentage inhibitions bucil (15
are shown for the concentration of each platinum
agent (> 50°, inhibition).
which the widest distribution oc-
bove and below the 50% cut-off
e Fig. 1). Sensitivity to all agents
i in only 2 untreated patients
Resistance to all agents was seen
reated patients (4, 5) and in one
14). In untreated patients without
;y to thiotepa, drugs which still
-ytotoxicity were phosphoramide
(3, 9), cis-platinum (6, 9, 13) and
n (12). Cultures generally showed
resistance or sensitivity to phos-
le mustard and thiotepa. Despite
sensitivity to 10-3 mg/ml of
and 10-2 mg/ml phosphoramide
some tumours from the treated
ill showed sensitivity to chloram-
5), treosulfan (20, 21) and cis-
(20, 22).
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FIG. 2. The range of sensitivity to antimetabolites shown by cultures of tumour cells from untreated
(A) and treated (B) patients. All concentrations are in mg/ml. 5FU 5-fluorouracil; MTX metho-
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No clear-cut correlation between histo-
logy and drug sensitivity was found except
for cyclophosphamide, for which only 1/4
well-differentiated tumours showed sensi-
tivity, whilst 5/7 poorly differentiated
tumours showed sensitivity.
Antimetabolites
The spectrum of sensitivity to the anti-
metabolites tested is shown in Fig. 2.
5-Fluorouracil and Cytosar showed the
greatest cytotoxicity in the untreated
group. Methotrexate was inhibitory at the
50% level in only 3 cultures from the un-
treated group; because of its phase
specificity, increasing concentrations did
not generally increase the level of inhibi-
tion. 6-Mercaptopurine was cytotoxic
against only 2 tumours at 10-1 mg/ml.
Comparison of the curves for treated and
untreated patients showed an overall
decrease in sensitivity inthe treatedgroup
to all antimetabolites tested.
Antimitotics
The spectrum of sensitivity to vincris-
tine and vinblastine is shown on the left
of Fig. 3. Both drugs showed similar acti-
vity against untreated tumours; as expec-
ted with phase-specific agents, the level of
inhibition was dose-independent for most
tumours, though this was more frequent
with vinblastine than vincristine. In
treated tumours vincristine showed con-
siderably less activity, all tumours being
resistant, but vinblastine, whilst less
active, was still cytotoxic to some tumours
from treated patients.
Antibiotics
The spectrum of sensitivity to the anti-
biotics is shown on the right of Fig. 3.
Although the peak plasma concentration
of actinomycin D was - 7.5 x 10-5 mg/ml
(Tattersall et al., 1975), the drug was
routinely tested at 5 x 10-8, 5 x 10-9 and
5 x 10-10 mg/ml because of its extreme
in vitro cytotoxicity at higher concentra-
tions. Tumours were sensitive ( > 500/o
inhibition) at all concentrations tested,
with only one exception. Tumours from
patients treated with FAT or VAT still
displayed in vitro sensitivity, though this
was reduced in 2 patients.
Adriamycin showed marked activity at
10-2 and 10-3 mg/ml in the untreated
group, which was considerably reduced in
treated tumours. Bleomycin also showed
more activity against untreated tumours
than against treated tumours.
Miscellaneous agents
Of the other agents tested routinely no
useful activity against tumour cells was
demonstrated by procarbazine or warfarin
at concentrations of 10-1 mg/ml. Nore-
thisterone acetate was effective against
10/15 specimens at 10-1 mg/ml but only
against 2/18 at 10-2 mg/ml. At concentra-
tions of 10-1 mg/ml medroxyprogesterone
acetate and methylprednisolone acetate
were effective against 4/10 specimens at
levels of inhibition of 30-50%.
Correlation of in vitro results with clinical
response for individual patients
Patients from whom tumour samples
were obtained were subdivided into (i)
those receiving first-line chemotherapy
with or without irradiation, and (ii) those
receiving second-line chemotherapy. All
patients had Stage III or IV disease.
Correlations are summarized in Table III.
A positive correlation was obtained be-
tween in vitro sensitivity and in vivo
response in 8/8 patients from the group
receiving first-line chemotherapy, either
as a single agent or in combination. Six of
the 8 responses were complete, one was
partial and one patient failed to show any
response to thiotepa, which also was not
cytotoxic against her tumour cells in vitro.
In patients receiving second-line chemo-
therapy, 3 showed both in vitro sensitivity
and clinical response to the second-line
agents used, which included vinblastine
and treosulfan; one was resistant to cyclo-
phosphamide in vitro and failed to show
anyclinicalresponse.Threepatientsshowed
in vitro sensitivity and failed to show
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FIG. 3. The range of sensitivity to antimitotics and antibiotics shown by cultures of tumour cells
from untreated (A) and treatedl (B) patients. All concentrations are in mg/ml. VLB vinblastine;
VCR vincristine; AMD-actinomycin D; ADM adriamycin; BLM bleomycin.
clinical response. The tumour cells from
2 of these showed in vitro sensitivity to
only 1 of the 3 agents used to treat them.
Sensitivity oftumour cellsfrom asciticftuids
of patients on the FAT regime
Cells from ascitic-fluid samples of 2
patients on the FAT regime were tested for
drug sensitivity after about 12 months'
treatment. The first specimens received
were assessed morphologically as sensitive
to 5-fluorouracil, actinomycin D and
thiotepa. The sensitivity of subsequent
samples is shown in Table IV. The cells
from B.W. showed reduced sensitivity to
actinomycin D and were insensitive to
19)6
ININ VITRO CHEMOSENSITIVITY OF HUMAN OVARIAN TUMOURS
TABLE III. Comparison c
with in vivo response
advanced ovarian carciT
Clinical respon(lert
Sellsit
in vi'
A
6 CR
I PR
Clinical non-respon(ler 0
A Patients receiving first,-
(n=8).
B Patients receiving seconl(
(n= 7).
* Sensitive, > 50/ inlwibitiob
inhibition.
t See Materials an(l Methlod
response; CR complete, PR part
I The in vitro sensitivity
ttumours was equivocal, becau
(dIrugs withl variable in vitro ac
their treatment.
thiotepa. The fluid Samp
was taken 4 months after
during that time the patier
on the same chemotherap
the sensitivity to thiotepa
the normal range but sensi
mycin ID was undiminishe
there was a marked reducti
to actinomycin ID, and
thiotepa and 5-fluorouraci
the lowest concentrations
DISCUSSIOs
The results presented in
cate that the monolayer
capable ofdemonstrating i
tions in the chemosensiti'
ovarian tumours in vitro.
chemotherapy group, corr
in vitro sensitivity and i
5fin vitro results was positive in all patients (8/8), compared
in patients with with 4/7 (57%0) in the second-line chemo-
ioma therapy group. Combinations of drugs
ive* Resistant* selected for first-line chemotherapy on the
itro in vitro basis ofthe invitroresultswere5-fluoroura-
cil, actinomycin D and thiotepa, or vin- B A B blastine, actinomycin D and thiotepa.
3 PR 0 0 Vinblastine and treosulfan were selected
3+ 1 for second-line chemotherapy. Numbers
in each treatment group were too small to
linle chemotherapy comment on the significance of these
I-line clhemothierapy results, but the combinations selected
gave an adequate complete-response rate.
n; resistant <500, Cultures of tumour cells from treated
Is for definition of patients showed less chemosensitivity
;al response. than cultures from untreated patients.
se fombinatientsof Although the treated patients had re-
tiv-ity were use(l in ceived thiotepa, FATorVATtheirtumours
showed an overall reduction in sensitivity
le B from F.L. to other drugs tested.
Sample A, and Primary cultures of human tumours
ithad contud should provide a good model for the ,it had continued
)y. In Sample A screening ofagents with potential activity
was lower than against a particular tumour type. In
tivity to actino- Table V, drugs have been ranked accord-
Id. In Sample B ing to their effectiveness in the in
ion in sensitivity vitro system. With the exception of
sensitivity to actinomycinD, alldrugs in the maximum-
1 was reduced at activity category are already favoured
agents for the treatment of ovarian car- tested. cinoma. The drugs in the lower-activity
categories have also been found effective
in evoking clinical responses in some
this study indi- patients, with the exception ofvinblastine,
system used is which is clinically ineffective (Young et al.,
individual varia- 1974). Thus the in vitro system seems
vities of human capable of predicting those agents which
In the first-line are likely to be useful in the treatment of
-elation between ovarian carcinoma.
n vivo response Phosphoramide mustard, the metabo-
TABLE IV. The % inhibition produced in vitro by FAT on cellsfrom the asciticfluid of
two patients on this regime
5-14'luorouracil
~_-_
(10-3)
46
54
47
(10-4)
42
51
Actinomycin D
C-~
(5 X 1(-8) (5 X 10-9) (5 X 1 1I0)
67 69 70
95 95 96
94 76 42
r
-
(10-2)
58
57
74
Tliiotepa
(10-3)
:36
:36
(10-4)
0
29
8
* All concentrations are shiown in mg/ml.
Sample B was taken 4 monithls after Sample A, (lutring whvichl time tile patici4t lha(d continued to receive
FAT.
Patienit,
B.W.
F.L.(A)
(B)
(10-2)*
79
83
79
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TABLE V.-The ranking of chemotherapeutic agents according to their in vitro activity
Maximum
Actinomycin D
cis-Platinum
Cyclophosphamide
Chlorambucil
Thiotepa
Treosulfan
Mustine
5-Fluorouracil
Moderate
Adriamycin
Cytosine arabinoside
Vinblastine
Occasional
Bleomycin
Methotrexate
Norethisterone acetate
Medroxyprogesterone acetate
Methylprednisolone acetate
Hexamethylemelamine
Vincristine
None
6-Mercaptopurine
Procarbazine
Warfarin
lite of cyclophosphamide which was used,
showed in vitro activity against 50% ofthe
tumours against which it was screened, a
figure which approximates to the response
rate expected with this drug. The suit-
ability of this compound for screening
cyclophosphamide activity in vitro cannot
unfortunately be proven from the study,
since patients did not receive cyclophos-
phamide. The precursor can be converted
either to phosphoramide mustard or to
carboxyphosphamide enzymically in the
tumour cell and the latter compound
shows considerably less cytotoxicity (Con-
nors et al., 1974). Cellular levels of the
relevant enzyme are therefore important,
and it may be that the use of phosphora-
mide mustard exaggerates the potential
cytotoxicity of cyclophosphamide for a
particular tumnour.
Specimens were found to exhibit differ-
ent sensitivities to 6 alkylating agents;
complete resistance or sensitivity was
rare. These findings parallel those made on
the sensitivity of mouse L1210 leukaemic
cells to alkylating agents (Schabel et al.,
1978) and belie the belief that sensitivity
to alkylating agents is an all-or-none
phenomenon. In this study it was found
that tumours from patients treated with
thiotepa showed greater resistance to
phosphoramide mustard than did tumours
from untreated patients, which parallels
the findings that cyclophosphamide-resis-
tant L1210 leukaemia cells showed a 10-
100-fold increase in resistance to thiotepa
(Schabel et al., 1978). The in vitro findings
of this study, together with the observa-
tion that the toxicity of alkylating agents
in combination is not always additive
(Schabel et al., 1978) suggests that there
may be a role for the combined use of
alkylating agents in the treatment of
advanced ovarian carcinoma. The appar-
ently greater sensitivity of poorly differ-
entiated tumours to cyclophosphamide
may also be of clinical relevance.
Actinomycin D was found to be the
most effective antibiotic, as well as one of
the most effective agents in vitro. The
concentration of 5 x 10-10 mg/ml which
was tested was many times less than the
peak plasma concentration achievable in
humans of 7-5 x 10-5 mg/ml (Tattersall
et al., 1975) but this was still sufficient to
produce > 90% inhibition in most speci-
mens tested. The drug would seem to have
considerable potential, but in animal
models it has been shown that, whilst
cytotoxic in vitro (10-4-10-6 mg/ml) it
enhanced tumour growth in vivo (Wilson,
1976). The drug has not been used as a
single agent in the treatment of ovarian
carcinoma, but has been used with 5-
fluorouracil and cyclophosphamide, when
it was felt that it was merely adding to
toxicity (Barlow & Piver, 1977). The
observation that the sensitivity to actino-
mycin D decreased after treatment with
FAT suggests that the agent may be mak-
ing a useful contribution to cell kill.
The sensitivity of 42% of tumours to
hexamethylmelamine was of interest
since, although the exact mechanism is
unknown, it is thought to require activa-
tion in vivo, possibly involving N-de-
methylation byhepatic microsomes (Rutty
& Connors, 1977; Rutty et al., 1978).
The results suggest either that the drug
can exert some cytotoxic effect in its
native form, or that some tumour cells
are capable of metabolizing the drug to
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an activeform. Procarbazine, anotherdrug
which requires in vivo activation, never
showed in vitro activity. Although war-
farin has been suggested as having a
direct anti-tumour effect (Hilgard &
Thornes, 1976) we found no in vitro
activity against ovarian tumour cells.
Progestogens, as has been suggested
(Briggs et al., 1967; Malkasian et al., 1977)
were found to show some useful activity
in a small proportion of tumours, but no
in vivo data are available on the relevant
patients for comparison. Methylpredni-
solone acetate, againthoughtto be capable
ofa direct anti-tumour effect (Liebermann
et al., 1977) was found to have some slight
activity.
Considerable interest has been centred
on the use of the clonogenic assay for in
vitro screening of the drug sensitivity of
human ovarian tumours (Alberts et al.,
1980). In the clonogenic assay the chemo-
sensitivity of the "stem-cell" population
of the tumour is specifically determined,
whereas in a monolayer of tumour cells
the chemosensitivity of the total dividing
cell population is measured. In advanced
ovarian cancer, where rapid debulking is
important, it may be that the latter assay
is of more relevance, the chemosensitivity
of the "stem-cell" population becoming
more important in the minimum ( < 2 cm
diameter) or microscopic residual-disease
situation. Preliminary experiments using
cell lines indicate that the clonogenic and
monolayer assays can give similar results
for a particular drug (Wilson et al.,
1981, unpublished data). The monolayer
system, with its potential for multiple drug
screening, ease ofperformance and quanti-
tation, may therefore provide a useful tool
for the in vitro study ofthe drug sensitivity
of human ovarian tumours.
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